Kalaris Therapeutics to Present First-in-Human Data for Novel Dual-Targeting AMD Therapy TH103
核心洞察
Kalaris Therapeutics (搜索) will present Phase 1 clinical data for TH103, a novel dual-targeting VEGF (搜索) and HSPG (搜索) inhibitor, at the 49th Annual Meeting of the Macula Society in February 2026.
TH103 was engineered by VEGF (搜索) pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention for treating neovascular age-related macular degeneration (搜索).
The presentation will include safety, tolerability, pharmacokinetics and early efficacy outcomes from a single ascending dose study in treatment-naive neovascular AMD patients.
Kalaris Therapeutics (搜索) will present first-in-human clinical data for its investigational therapy TH103 at the 49th Annual Meeting of the Macula Society, scheduled for February 25-28 in San Diego, California. The presentation marks a significant milestone for the novel dual-targeting approach to treating neovascular age-related macular degeneration (搜索) (AMD).
Novel Dual-Targeting Mechanism
TH103 represents a novel investigational therapy engineered by VEGF (搜索) scientific pioneer Dr. Napoleone Ferrara to achieve enhanced VEGF inhibition and increased intraocular retention. The therapy targets both VEGF and heparan sulfate proteoglycans (HSPG (搜索)), representing a differentiated approach to treating retinal diseases compared to current anti-VEGF therapies.
The Phase 1 single ascending dose study evaluated TH103 in patients with treatment-naive neovascular age-related macular degeneration (搜索) following intravitreal administration. The presentation will include comprehensive safety, tolerability, pharmacokinetics and early efficacy outcomes from this first-in-human evaluation.
Scientific Presentation Details
Dr. Dean Eliott, S.E. Gragoudas Professor of Ophthalmology at Harvard Medical School and Director Emeritus of Retina Service at Massachusetts Eye & Ear Infirmary, will present the data during the "Neovascular AMD I: Clinical Trials" session on Thursday, February 26, 2026, at 8:15 am PT in the Southpointe Ballroom at Hotel Del Coronado.
The presentation, titled "First-in-Human Evaluation of TH103, a Dual-Targeting VEGF (搜索) and HSPG (搜索) Inhibitor: Phase 1 Single Ascending Dose Study in Treatment-Naïve Neovascular AMD," will be delivered to leading retinal specialists and clinical investigators attending the highly selective, invitation-only forum.
Clinical Development Context
The Macula Society Annual Meeting serves as a highly selective, invitation-only forum where internationally recognized retinal experts convene to present and critically evaluate emerging clinical data and novel therapeutic strategies in retinal vascular and macular disease. The selection of TH103 data for presentation at this prestigious venue underscores the potential significance of the dual-targeting approach.
Kalaris Therapeutics (搜索), founded by Dr. Napoleone Ferrara whose pioneering research led to the development of anti-VEGF (搜索) therapy, is dedicated to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions with major unmet medical needs. The company's focus on differentiated therapies for retinal diseases positions TH103 as a potentially important addition to the treatment landscape for neovascular AMD.